CONTENTS

NOTE TO THE READER............................................................................................1

LIST OF PARTICIPANTS............................................................................................3

PREAMBLE ................................................................................................................9
1. Background........................................................................................................9
2. Objective and Scope......................................................................................9
3. Selection of Topics for Monographs ...........................................................9
4. Data for Monographs ...............................................................................10
5. The Working Group ..................................................................................11
6. Working Procedures ...............................................................................11
7. Exposure Data..........................................................................................12
8. Studies of Cancer in Humans .................................................................14
9. Studies of Cancer in Experimental Animals ..........................................17
10. Other Data Relevant to an Evaluation of Carcinogenicity
and its Mechanisms ......................................................................................20
11. Summary of Data Reported ..................................................................22
12. Evaluation...............................................................................................23
13. References...............................................................................................28

GENERAL REMARKS............................................................................................33

THE MONOGRAPHS................................................................................................39

SOME TRADITIONAL HERBAL MEDICINES......................................................41
A. Introduction................................................................................................43
  1. History of use of traditional herbal medicines ................................43
     1.1 The role of herbal medicines in traditional healing ...............43
     1.2 Introduction of traditional herbal medicines into Europe, the USA
         and other developed countries .............................................44
  2. Use of traditional herbal medicines in developed countries ............46
     2.1 Origin, type and botanical data ...........................................46
     2.2 Medicinal applications, beneficial effects and active components.46
     2.3 Trends in use .....................................................................46
  3. Awareness, control, regulation and legislation on use .......................50
     3.1 WHO guidelines for herbal medicines ..............................50
3.2 The European Union .................................................................51
3.3 Individual countries .................................................................55
4. References ......................................................................................66

B. Aristolochia species and aristolochic acids .................................69
1. Exposure data ..............................................................................69
   1.1 Origin, type and botanical data ..............................................69
   1.2 Use .......................................................................................76
   1.3 Chemical constituents ..........................................................76
   1.4 Active components ...............................................................78
   1.5 Sales and consumption .........................................................79
   1.6 Components with potential cancer hazard: aristolochic acids ....79
2. Studies of cancer in humans .........................................................84
   2.1 Case reports ..............................................................85
   2.2 Prevalence of urothelial cancers among patients with Chinese
       herb nephropathy .................................................................86
3. Studies of cancer in experimental animals .....................................87
   3.1 Oral administration ..............................................................87
   3.2 Intraperitoneal administration ...............................................88
   3.3 Subcutaneous administration ................................................88
4. Other data relevant to an evaluation of carcinogenicity and
   its mechanisms ...........................................................................89
   4.1 Absorption, distribution, metabolism and excretion .............89
   4.2 Toxic effects .........................................................................91
   4.3 Reproductive and developmental effects ..............................94
   4.4 Genetic and related effects ....................................................96
   4.5 Mechanistic considerations ................................................115
5. Summary of data reported and evaluation ...................................116
   5.1 Exposure data ..............................................................116
   5.2 Human carcinogenicity data ...............................................117
   5.3 Animal carcinogenicity data ................................................117
   5.4 Other relevant data ..............................................................117
   5.5 Evaluation ..........................................................................118
6. References ......................................................................................118

C. Rubia tinctorum, Morinda officinalis and anthraquinones ............129
1. Exposure data ..............................................................................129
   1.1 Origin, type and botanical data ............................................129
   1.2 Use ..............................................................130
   1.3 Chemical constituents ........................................................131
   1.4 Sales and consumption .........................................................132
   1.5 Component(s) with potential hazard (1-hydroxyanthraquinone;
       1,3-dihydroxy-2-hydroxymethylanthraquinone (lucidin)) ..........132
SOME MYCOTOXINS................................................................. 169
AFLATOXINS .................................................................................... 171
  1. Exposure data ................................................................................ 171
  2. Studies of cancer in humans ......................................................... 193
  3. Studies of cancer in experimental animals ..................................... 210
  4. Other data relevant to an evaluation of carcinogenicity
     and its mechanisms ...................................................................... 215
  5. Summary of data reported .......................................................... 245
  6. References .................................................................................. 249
Annex. Aflatoxins in foods and feeds: fungal sources, formation
     and strategies for reduction ......................................................... 275
FUMONISIN B1 .............................................................................. 301
  1. Exposure data ............................................................................. 301
  2. Studies of cancer in humans ......................................................... 309
  3. Studies of cancer in experimental animals ..................................... 311
  4. Other data relevant to an evaluation of carcinogenicity
     and its mechanisms ...................................................................... 316
  5. Summary of data reported and evaluation ...................................... 343
  6. References .................................................................................. 345
NAPHTHALENE ............................................................................. 367
  1. Exposure data ............................................................................. 367
  2. Studies of cancer in humans ......................................................... 385
  3. Studies of cancer in experimental animals ..................................... 385
  4. Other data relevant to an evaluation of carcinogenicity
     and its mechanisms ...................................................................... 389
  5. Summary of data reported and evaluation ...................................... 416
  6. References .................................................................................. 418
STYRENE ..................................................................................... 437
  1. Exposure data ............................................................................. 437
  2. Studies of cancer in humans ......................................................... 463
  3. Studies of cancer in experimental animals ..................................... 475
  4. Other data relevant to an evaluation of carcinogenicity
     and its mechanisms ...................................................................... 479
  5. Summary of data reported and evaluation ...................................... 518
  6. References .................................................................................. 522
SUMMARY OF FINAL EVALUATIONS ........................................ 551
LIST OF ABBREVIATIONS USED IN THIS VOLUME .................. 553
CUMULATIVE INDEX TO THE MONOGRAPHS SERIES .......... 557
NOTE TO THE READER

The term ‘carcinogenic risk’ in the IARC Monographs series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.